Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
CD26 as a Prognostic Marker in Allogeneic Hematopoietic Stem Cell Transplantation
23 Pages Posted: 5 Jun 2020
More...Abstract
Background: The success of hematopoietic stem cell transplantation (HSCT) depends upon donor stem cell harvest. Conventionally CD34 has been considered as marker of hematopoietic stem cells; however, the association of CD34+ cells with post-transplant outcomes has not been consistent. Current efforts are focused on identification of new markers that serve as potential predictors of post-transplant clinical outcome.
Methods: This study includes donor harvests collected from twenty-three allogeneic donors during period 2008-2009 and respective transplant recipients followed for clinical outcomes till March 2019. Percent CD26+ and CD34+ cells in PBSC harvest were analyzed using flow cytometry. Infused dose of CD26+ and CD34+ cells was evaluated for its association with various clinical outcomes.
Findings: Median donor and patient age was 28 and 24 years, respectively; 13 and 17 were males, respectively. Median CD34br CD45lo HSC expression was 0·57% (IQR 0·24-1·03) while median CD26 expression was 19·64% (IQR 8·96-33·56) of all nucleated cells. Lower CD26 expression correlated with lower risk of developing aGvHD (p=0·056). Higher infused CD26+ cell dose was associated with early WBC engraftment (p=0·004), higher risk of CMV reactivation (p=0·020) and a tendency to lower overall survival (p=0·066). There was no correlation between infused CD26+ and CD34+ cell dose.
Interpretation: This forms the first study suggesting CD26 expression on donor harvest and CD26+ cell dose may serve as potential markers for transplant outcomes. If validated further in larger studies, it may be helpful in management of GvHD prophylaxis and improving survival with risk-based tailored therapeutics.
Funding Statement: This study was funded by Indian Co-operative Oncology Network- Academic Research Organization, Mumbai, India.
Declaration of Interests: Authors declare no potential financial conflicts of interest.
Ethics Approval Statement: The study was approved by the institutional ethics committee. All patients and donors provided consent for study participation.
Keywords: CD26 expression; Flow cytometry; Stem cell transplantation; Donor stem cell harvest; Engraftment; Graft versus host disease; CMV reactivation; Survival
Suggested Citation: Suggested Citation